Investors should turn their attention to Alcon for consistent returns, according to JPMorgan. The bank has upgraded the eye care company’s stock from neutral to overweight, while also increasing its price target to $89.30 per share from $79.80. This implies an 11% upside from Wednesday’s closing price of $80.24. The upgrade comes after Alcon reported better-than-expected second-quarter results and raised its full-year earnings guidance. Despite the positive news, the stock only saw a marginal increase. However, analyst David Adlington believes that Alcon has several growth drivers, including its implantable segment and higher equipment volume. Adlington stated, “The positive earnings’ momentum looks set to continue.” Alcon’s stock has already gained over 17% in 2023.